BONESUPPORT‚Ñ¢¬†, an emerging leader in orthobiologics for the management of bone voids, today announced the launch of BONIFY‚Ñ¢, a demineralized bone matrix (DBM) product line, expanding the company‚Äôs product portfolio in the US market. BONIFY will be launched at the American Academy of Orthopedic Surgeons (AAOS) 2019 Annual Meeting in Las Vegas, NV, March 13-15, 2019.
BONIFY¬†is a unique bone graft composed of 100 percent DBM that offers¬†osteoinductive potential to aid in the bone healing process.¬†BONIFY¬†serves to complement the company‚Äôs proprietary platform CERAMENT¬Æ¬†which offers osteoconductive properties and has been shown to remodel to host bone within 6-12 months.
‚ÄúThese are exciting times for BONESUPPORT. With today‚Äôs launch of¬†BONIFY, we are taking an important step in creating a broad and complementary US product offering, expanding our access to a larger segment of the US bone graft market.¬†BONIFY¬†complements CERAMENT¬Æ BONE VOID FILLER which we, since October 2018, are selling direct via our own US distributor network‚Äù, said¬†Emil Billb√§ck,¬†CEO of¬†BONESUPPORT.